Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)

A. Yoshimi, Koji Kato, N. Maeda, T. Matsuyama, S. Kojima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78%) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume41
Issue number2
Publication statusPublished - Jan 1 2000

Fingerprint

Hepatic Veno-Occlusive Disease
Tissue Plasminogen Activator
Bone Marrow Transplantation
Subdural Hematoma
Therapeutics
Transplantation
Hemorrhage
Safety
Lung

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA). / Yoshimi, A.; Kato, Koji; Maeda, N.; Matsuyama, T.; Kojima, S.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 41, No. 2, 01.01.2000, p. 103-108.

Research output: Contribution to journalArticle

@article{bd01d6c7b6174878a79580680135a5e6,
title = "Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)",
abstract = "Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78{\%}) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.",
author = "A. Yoshimi and Koji Kato and N. Maeda and T. Matsuyama and S. Kojima",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "103--108",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "2",

}

TY - JOUR

T1 - Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)

AU - Yoshimi, A.

AU - Kato, Koji

AU - Maeda, N.

AU - Matsuyama, T.

AU - Kojima, S.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78%) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.

AB - Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78%) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.

UR - http://www.scopus.com/inward/record.url?scp=0034131880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034131880&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 103

EP - 108

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 2

ER -